ALLR — Allarity Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1860657 ·
Last close
$1.16
Market Cap
$18.54M
52W High
$1.84
52W Low
$1.03
ADV30
170,225
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 25,000 | — | -2,688,000 | -2,750,000 | 34,923,000 | 19,812,000 | 28,003,000 |
| Dec 2025 | 320,000 | — | -2,918,000 | -3,373,000 | 18,258,000 | 14,687,000 | 8,430,000 |
| Sep 2025 | 0 | — | -2,518,000 | -2,806,000 | 20,796,000 | 16,895,000 | 8,785,000 |
| Jun 2025 | 0 | — | -4,133,000 | -2,320,000 | 21,205,000 | 17,801,000 | 9,038,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,627,000
Investing CF
$-64,000
Financing CF
$19,245,000
CapEx
$-64,000
Dividends Paid
—
Buybacks
$-3,452,000
EPS Diluted TTM
$-0.76
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-132,947,000
Inventory
—
Receivables
$1,082,000
ST Investments
—
EBIT TTM
$-10,892,000
Pretax Income TTM
$-11,249,000
Interest Exp TTM
$357,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$345,000
EBITDA
$-12,596,000
Free Cash Flow
$-20,963,750
Enterprise Value
$20,776,868
Total Cash
$19,812,000
Total Debt
$21,496,000
Shares Out
15,910,724
Trailing EPS
$-0.70
Book Value
$0.44
ROE
-87.9%
ROA
-23.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 320,000 | -12,605,000 | -11,231,000 | 18,258,000 | 8,430,000 | — | -14,820,000 |
| Dec 2024 | 0 | -17,538,000 | -24,515,000 | 22,650,000 | 10,839,000 | — | -17,352,000 |
| Dec 2023 | 0 | -17,129,000 | -11,901,000 | 11,862,000 | 14,613,000 | — | -12,745,000 |
| Dec 2022 | 0 | -16,892,000 | -16,058,000 | 14,544,000 | 12,654,000 | — | -16,817,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.97
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NEUP | Neuphoria Therapeutics Inc. | $19.13M | $3.54 | — |
| PTN | PALATIN TECHNOLOGIES INC | $17.79M | $10.00 | — |
| OTLC | Oncotelic Therapeutics, Inc. | $17.74M | $0.04 | — |
| HOWL | Werewolf Therapeutics, Inc. | $19.58M | $0.40 | — |
| LPCN | Lipocine Inc. | $19.87M | $2.41 | — |
News headlines (Yahoo Finance, 1h cache)
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
2026-07-07 12:00 · Yahoo
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
2026-07-06 13:40 · Yahoo
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
2026-06-30 12:00 · Yahoo
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
2026-06-19 13:40 · Yahoo
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
2026-06-18 12:00 · Yahoo
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
2026-06-03 13:40 · Yahoo
Are Medical Stocks Lagging Bioventus (BVS) This Year?
2026-05-18 13:40 · Yahoo
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
2026-05-15 20:30 · Yahoo
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
2026-05-08 12:45 · Yahoo
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
2026-05-05 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.